GENZYME CORPORATION for GENZYME CORPORATION
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
H.R. 1249/S.23, America Invents Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Health Issues HCR
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act 340B issues
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Taxation/Internal Revenue Code TAX
Implemenation of P.L. 111-148, Patient Protection & Affordable Health Care Act Excise Tax for Drugs and Biologics
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Medicare/Medicaid MMM
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative policy Deficit reduction proposals related to debt ceiling
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Pharmacy PHA
S.606 - Creating Hope Act of 2011 Prescription Drug User Fee Act reauthorization S.296/H.R.2245 Preserving Access to Life-Saving Medication Act H.R.2482 Drug Safety Enhancement Act
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on form LD-1, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARA FROELICH | Vice President |
| KATHLEEN HOLCOMBE | Senior Policy Advisor |
| MARY MCGRANE | Senior Vice President |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| SANOFI, SA | France | France | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.